Deliargyris Efthymios's most recent trade in Cytosorbents Corp was a trade of 16,233 Common Stock done at an average price of $1 . Disclosure was reported to the exchange on Jan. 17, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cytosorbents Corp | Efthymios Nikolaos Deliargyris | Chief Medical Officer | 17 Jan 2025 | 16,233 | 403,025 (1%) | 0% | 1 | 16,233 | Common Stock | |
| Cytosorbents Corp | Efthymios Nikolaos Deliargyris | Chief Medical Officer | 17 Jan 2025 | 16,233 | 0 | - | - | Subscription Rights (right to buy) | ||
| Cytosorbents Corp | Efthymios Nikolaos Deliargyris | Chief Medical Officer | Other type of transaction at price $ 0.00 per share. | 17 Jan 2025 | 16,233 | 16,233 | - | - | Series A Right Warrants | |
| Cytosorbents Corp | Efthymios Nikolaos Deliargyris | Chief Medical Officer | Other type of transaction at price $ 0.00 per share. | 17 Jan 2025 | 16,233 | 16,233 | - | - | Series B Right Warrants | |
| Cytosorbents Corp | Efthymios Nikolaos Deliargyris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Cytosorbents Corp | Efthymios Nikolaos Deliargyris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Cytosorbents Corp | Efthymios Nikolaos Deliargyris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2024 | 86,000 | 86,000 | - | - | Stock Option (Right to Buy) | |
| Cytosorbents Corp | Efthymios Nikolaos Deliargyris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2024 | 61,000 | 409,433 (1%) | 0% | 0 | Common Stock | |
| Cytosorbents Corp | Efthymios Deliargyris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2024 | 47,088 | 47,088 | - | - | Stock Option (Right to Buy) | |
| Cytosorbents Corp | Deliargyris Efthymios | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 1.33 per share. | 13 Dec 2023 | 22,557 | 348,433 (0%) | 0% | 1.3 | 30,001 | Common Stock |
| Cytosorbents Corp | Efthymios Deliargyris | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 13 Dec 2023 | 7,894 | 7,894 | - | - | Common Stock Warrant (Right to Buy) | |
| Cytosorbents Corp | Efthymios Deliargyris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jul 2023 | 78,000 | 78,000 | - | - | Stock Option (right to buy) | |
| Cytosorbents Corp | Efthymios Deliargyris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jul 2023 | 55,000 | 331,648 (0%) | 0% | 0 | Common Stock | |
| Cytosorbents Corp | Efthymios Deliargyris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jul 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Cytosorbents Corp | Efthymios Deliargyris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2022 | 300,000 | 300,000 | - | - | Stock Option (right to buy) | |
| Cytosorbents Corp | Efthymios Deliargyris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2022 | 74,000 | 74,000 | - | - | Stock Option (right to buy) | |
| Cytosorbents Corp | Efthymios Deliargyris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2022 | 55,000 | 228,384 (0%) | 0% | 0 | Common Stock | |
| Cytosorbents Corp | Efthymios Deliargyris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2022 | 52,000 | 283,384 (0%) | 0% | 0 | Common Stock | |
| Cytosorbents Corp | Efthymios Deliargyris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2021 | 63,250 | 63,250 | - | - | Stock Option (right to buy) | |
| Cytosorbents Corp | Efthymios Deliargyris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 8.99 per share. | 12 Apr 2021 | 40,000 | 183,000 (0%) | 0% | 9.0 | 359,600 | Common Stock |